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Suzanne van Dorp,1,2 Floor Pietersma,2 Matthias Wo¨lfl,3 Leo F. Verdonck,1 Eefke J. Petersen,1
Henk M. Lokhorst,1 Edwin Martens,4 Matthias Theobald,1 Debbie van Baarle,2
Ellen Meijer,1 Ju¨rgen Kuball1,2Chronic graft-versus-host-disease (cGVHD) is the major cause of late morbidity and mortality after alloge-
neic stem cell transplantation. B cells have been reported to be involved in mediating cGVHD. To assess
whether preemptive host B cell depletion prevents extensive cGVHD after allogeneic reduced-intensity con-
ditioning transplantation (RICT), 173 patients treated with RICT for various hematologic diseases, who had
or had not received Rituximab (Rtx) within 6 month prior to RICT, were analyzed retrospectively. Rtx treat-
ment within 6 months prior to RICT reduced extensive cGVHD significantly from 45.8% to 20.1%. We hy-
pothesize that most likely host B cells initiate cGVHD, and thus, host B cell depletion prior to RICT by Rtx
might be a valuable strategy to reduce extensive cGVHD after RICT.
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Chronic graft-versus-host-disease (cGVHD) is the
major long-term complication of allogeneic stem cell
transplantation (allo-SCT), as up to 70% of all survi-
vors of allo-SCT beyond day 100 develop cGVHD
[1-3]. Several lines of investigation indicate that B cells
are involved in the development of cGVHD [2,4], and
B cell depletion using the monoclonal anti-CD20 anti-
body Rituximab (Rtx) has demonstrated benefit in the
treatment of steroid-refractory cGVHDwith a success
rate of up to 70%[5-8].Givenpoor clinical responses in
patients with steroid-refractory cGVHD [2] a potential
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6/j.bbmt.2009.02.005pursuit. To date, the answer to this question has been
approached by others, but remains unanswered. A
study of patients after myeloablative allo-SCT sug-
gested no difference in cGVHD in 35 patients treated
with Rtx as part of the allo-SCT conditioning regimen,
but indicated a possible decrease in overall acute
GVHD (aGVHD) incidence [9]. Therefore, we stud-
iedwhether depletion of host B cells prior to transplan-
tation by Rtx can reduce the incidence of this quality of
life and life-threatening complication in patients who
underwent allogeneic reduced-intensity conditioning
transplantation (RICT). Patients with and without
Rtx treatment within 6months prior to RICTwere an-
alyzed retrospectively and were compared for the inci-
dence of aGVHD and cGVHD, graft-versus-leukemia
(GVL) effect, and overall survival (OS).DESIGN AND METHODS
Power Analysis and Selection of Patients
To calculate the minimum amount of patients
needed to see a significant difference in extensive
cGVHDbetween theRtx pretreated andnon-Rtx group
an effect size, thus the expected difference between 2
groups was set at 25%. The chi-square calculation indi-
cated that 18 patients per group were needed to achieve
a power of 80% (a5 0.05). One hundred seventy-three
patients with various hematologic diseases (Table 1),671
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Utrecht, from September 2001 until April 2007, were
included in this retrospective study, which allowed us
to further increase the number of Rtx-treated patients
to 29 Rtx patients and 144 control patients, which in-
creased the power from 80% to .99%. One patient in
the Rtx group had been treated with alemtuzumab 6
months prior to RICT. RICT was given as curative or
as rescue treatment to patients younger than 70 years
with an availableHLA-matched relatedor unrelated do-
nor (1 HLA class I or class II mismatch was allowed).
Patients were treated according to clinical protocolsTable 1. Patient Characteristics
Total Popu
N (%) 173
Median age (years) (range) 56 (20-
Median follow-up (months) (range) 28 (1-4
Sex % (female/male) 34/66
Disease, n
ALL 6
AML 29
MDS 8
CLL 13
CML 6
MM 62
NHL 32
SAA 6
Myelofibrosis 2
Other 9
Donor, n(%)
MRD 111 (64)
PMRD 10 (6)
MUD 38 (22)
PMUD 14 (8)
HLA-mismatch, n(%) 24 (14)
Patient male/donor female, n (%) 37 (21)
ATG as part of conditioning, n (%) 70 (41)
RT as part of pretreatment, n (%) 25 (15)
Remission before RICT, n (%)
CR 55 (32)
PR 74 (43)
NR/progression 44 (25)
Median time of Rtx treatment before RICT (months) (range) —
Duration of IS, n (%)
Short 89 (51)
Long 84 (49)
Organs affected by limited cGVHD, n (% of limited cGVHD)
Skin 16 (100
Liver 3 (19)
Organs affected by extensive cGVHD, n (% of extensive
cGVHD)
Skin 50 (78)
Liver 17 (27)
Oropharynx 56 (88)
Eyes 30 (47)
Lungs 12 (19)
Gut 7 (11)
Kidneys 2 (3)
Tendons/joints 2 (3)
Genitals 3 (5)
Pericard 1 (2)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia
chronic myelogenous leukemia; CR, complete remission; Disease, disease for
disease; HLA, human leukocyte antigen; IS, immunosuppression; MDS, myelody
NHL, non-Hodgkin lymphoma; NoRtx, no rituximab treatment within 6month
PR, partial remission; RICT, reduced-intensity conditioning transplantation; RT
SAA, severe aplastic anemia.
* P-values: Mann-Whitney U-test for age and follow-up; c2-test for other factapproved by the local ethics board and gave their
informed consent.Determination of B Cell Counts
Absolute B cell counts were determined in whole
blood using TRUcount tubes (Becton Dickinson,
Fullerton, CA), according to the manufacturers’ proto-
col. In brief, whole blood samples were incubated with
antihuman CD19 (fluorescein isothiocyanate [FITC]-
labeled; Becton Dickinson) in TRUcount tubes.
Erythrocytes were lysed with lysing buffer (Bectonlation Rtx No Rtx P-Value
29 144
69) 58 (29-67) 56 (20-69) .662
0) 21.9 (1-40) 28.8 (1-40) .011
28/72 35/65 .417
<.001
0 6
0 29
0 8
8 5
0 6
0 62
18 14
0 6
0 2
3 6
.925
19 (66) 92 (64)
1 (3) 9 (6)
7 (24) 31 (22)
2 (7) 12 (8)
3 (10) 21 (15) .547
5 (17) 32 (22) .551
11 (38) 59 (41) .761
5 (17) 20 (14) .639
.100
4 (14) 51 (35)
16 (55) 58 (40)
9 (31) 35 (24)
2.0 (1-6) — —
.235
12 (41) 77 (54)
17 (59) 67 (46)
) 5 (100) 11 (100) —
0 (0) 3 (27) .195
4 (80) 46 (78) .916
2 (40) 15 (25) .479
3 (60) 53 (95) .053
2 (40) 28 (47) .748
1 (20) 11 (19) .941
0 (0) 7 (12) .414
0 (0) 2 (3) .676
1 (20) 1 (2) .024
1 (20) 2 (3) .092
0 (0) 1 (2) .769
; ATG, antithymocyte globulin; CLL, chronic lymphocytic leukemia; CML,
which RICTwas given as treatment; cGVHD, chronic graft-versus-host
splastic syndrome; MM, multiple myeloma; MRD, matched related donor;
s prior to RICT; NR, no remission; PMRD, partial matched related donor;
, radiotherapy; Rtx, rituximab treatment within 6 months prior to RICT;
ors.
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(Becton Dickinson) flow cytometer. Results were ana-
lyzed with FACS DIVA software (Becton Dickinson).
Absolute B cell numbers were calculated according to
manufacturers’ protocol.
Conditioning Regimen before RICT
For patients with a matched-related donor, the
conditioning regimen consisted of fludarabin (Flu; 30
mg/m2/day i.v. for 3 days) and 1 fraction of low-dose
total body irradiation (TBI) (2 Gy). The transplanta-
tion with granulocyte-colony stimulating factor (G-
CSF) mobilized peripheral blood hematopoietic stem
cells (PBSCs) was performed after TBI. In the case
of an HLA-mismatched family donor or any unrelated
donor rabbit, antithymocyte globulin (ATG; 2 mg/kg/
day for 4 days) was added to the regimen and infused
before Flu was given. Patients with multiple myeloma
(MM), who were treated with RICT, within 3 months
after high-dose melfalan (200 mg/m2) and autologous
SCT, only received TBI.
Immunosuppression after allo-SCT
In the posttransplantation period all patients were
treated with the immunosuppressants cyclosporin A
(CsA) and mycophenolate mofetil (MMF). Patients re-
ceived 2 4.5 mg/kg/day CSA until day184 (short) or
day 1120 (long). Hereafter, CSA was tapered if no
GVHD was present. CSA dose was lowered in the
case of raised creatinin levels or severe side effects. Pa-
tients received 15 mg/kg/day MMF (maximum of 3 g/
day) until day128 (short) or184 (long), also followed
by tapering in the absence of GVHD.
aGVHD and cGVHD
aGVHD was diagnosed and graded according to
the Glucksberg criteria [10]; cGVHD was graded ac-
cording to the Seattle classification [11,12]. aGVHD
greater than grade 1 was treated with prednisone 1-2
mg/kg/day; in case of skin localization, topical predni-
sone treatment was applied. Additionally, CSA and
MMF doses were increased or continued. Steroid-re-
fractory aGVHD was treated with sirolimus, tacroli-
mus, Rtx, or more experimental drugs, such as
alemtuzumab and dacluzimab. cGVHD of the skin
was treated with topical prednisone. In severe cases of
extensive cGVHD, prednisone 1mg/kg/day was given.
Time to aGVHDand cGVHDwas calculated from the
date of transplantation until occurrence of aGVHD or
cGVHD.
Statistical Analysis
Progression free survival (PFS) was defined as the
probability of being alive with no indication of disease
progression. OS was defined as the probability of sur-
vival without considering the occurrence or nonoccur-rence of relapse. PFS and OS were measured in
months and calculated from the date of transplantation
until the date of the first signs of progression or last
date of follow-up. Incidence of aGVHD and cGVHD,
Epstein-Barr virus (EBV) and cytomegalovirus (CMV)
reactivations, 95% donor chimerism, and probabilities
of PFS and OS were calculated using the 1-Kaplan-
Meier method. Kaplan-Meier curves were generated
to illustrate survival, and the log-rank test was used
to compare survival curves between subgroups. Uni-
variate Cox regression was used to determine the prog-
nostic value of various variables for the development of
aGVHD and cGVHD, EBV, and CMV reactivation,
95% donor chimerism, PFS, and OS. These variables
included sex, age, disease type, HLA-mismatch, sex-
mismatch, ATG as part of conditioning regimen, ra-
diotherapy (RT) as part of the treatment regimen of
the prior disease, conditioning, remission state prior
to RICT, aGVHDgrade II-IV or III-IV, limited or ex-
tensive cGVHD, status of T cell and non-T cell chi-
merism, and application of Rtx. For aGVHD and
cGVHD, a univariate time-dependent Cox regression
analysis was used to assess its predictive value. Vari-
ables that had a value of P # .10 in univariate analysis
were included in a multivariate Cox regression analy-
sis, because the number of available potential predic-
tors exceeded the maximum allowed number. Rtx
treatment was always included in multivariate analysis.
For example, the effect of disease stage before RICT
was assessed first with univariate Cox regression anal-
ysis and when a P-value of\.10 was reached, in multi-
variate Cox analysis together with Rtx. We thereby
corrected for stage of disease. Not more than 7 vari-
ables were used at once in multivariate analysis.
Thereby, it was guaranteed that the compared groups
would not be too small. Variables were entered all at
once in the Cox model. We used a backward logistic
regression model to calculate the effect hierarchically.
Statistical analyses were performed with SPSS 15.0 for
Windows (SPSS Inc., Chicago, IL).
The significance of the difference between the B
cell counts on time points pre- and posttransplantation
of patients who received Rtx and of patients who did
not, was assessed by using a Mann-Whitney U-test.
Analyses were performed with GraphPad Prism 4.0
for Windows (GraphPad Software Inc., San Diego,
CA). A probability level of 5% (P\ .05) was consid-
ered significant in all analyses.RESULTS
Influence of Rtx Treatment Prior to RICTon B
Cell Counts post-RICT
One hundred seventy-three patients with hemato-
logic malignancies who underwent RICT were ana-
lyzed retrospectively (Table 1). Patients were divided
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Figure 1. B cell counts pre- and post-RICT in patients who received (white bars) and did not receive (black bars) Rtx within 6 months prior to RICT
compared to a healthy control group (gray bar). Statistical analyses compare B cell counts of patients of each time point to B cell counts of the healthy
control group. Counts before RICT (within 1 week), or months after RICTare indicated. Bars indicate median and range. Numbers indicate the number
of samples measured per time point. Only significant changes (P\.05) are indicated. Statistical analyses were performed with a Mann-Whitney U-test.
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ceive (no-Rtx, n 5 144) Rtx within 6 months prior to
RICT as B cell depletion has been reported to last
for up to 6 months [13-15]. The median time of the
last administration of Rtx before RICTwas 2.0months
(range: 1.0-6.0 months). Patients received 375 mg/m2
rituximab per application, and in 27 cases this was ad-
ministered in combination with chemotherapy (R-
CHOP/R-PECC; 6-8 cycles). One patient with EBV
reactivation postsolid organ transplantation received
3 single applications of Rtx, 1 patient received twice
Rtx for chronic active EBV infection. To investigateFigure 2. 1-Kaplan-Meier curves of aGVHD grade II-IV (A) and grade III-IV (B
(C) Onset of aGVHD grade III-IV in patients who received Rtx prior to RICTwhether B cell depletion with Rtx within 6 months
prior to RICT effects B cell counts pre- and post-
RICT, B cell counts from patients who did (n 5 5)
and did not receive Rtx (n 5 6) within 6 months prior
to RICT were investigated from the study cohort
when B cell counts were available prior and after
RICT at least until 9 months post-RICT. B cell counts
from patients were compared to B cell counts from
14 healthy controls (median: 212.5/mL; range:
88-418/mL). Median B cells counts pre-RICT (13.0/
mL; n 5 4) and 3 months post-RICT (23.5/mL; n 5
6) were significantly lower (P\ .01) in patients who) in patients who received Rtx prior to RICTand in patients who did not.
and in patients who did not.
Table 2. Multivariate Cox Regression Analysis of Outcome in
Terms of aGVHD Grade II-IV, aGVHD Grade III-IV, Total
cGVHD, Extensive cGVHD, Limited cGVHD, PFS, and
Nonrelapse Mortality
Acute GVHD
Grade II-IV
Univariate
P-Value
Multivariate
P-Value HR 95% CI
Disease .051 .806 1.022 0.861-1.212
No HLA mismatch .058 .065 2.189 0.951-5.034
No Rtx .610 .621 0.864 0.485-1.541
Acute GVHD Grade
III-IV
Univariate
P-Value
Multivariate
P-Value HR 95% CI
No Rtx .702 .733 .844 0.320-2.230
Biol Blood Marrow Transplant 15:671-678, 2009 675Dual Role for Host B Cells in RICTreceived Rtx compared to a healthy control group (n5
14) (Figure 1). In contrast, the median of B cell counts
in patients who did not receive Rtx prior to RICT did
not differ significantly before (182/mL; n 5 3) and 3
months after (148.5/mL; n 5 6) RICT compared to
the healthy control group (n 5 14). Six and 9 months
after RICT, no significant difference in B cell counts
was observed for both the Rtx and the no-Rtx group,
when compared to thehealthy control group (Figure1).
Thus, Rtx treatment within 6 months prior RICT re-
duces the total number of B cells post-RICT at least
until 3 months after RICT.No ATG .034 .041 2.574 1.039-6.379
Total cGVHD
Univariate
P-Value
Multivariate
P-Value HR 95% CI
No HLA
mismatch
.093 .895 1.066 0.409-2.779
No sex
mismatch
.036 .132 0.664 0.391-1.130
No Rtx .468 .528 1.241 0.634-2.427
No ATG .001 .002 2.216 1.339-3.667
No RT .099 .340 1.515 0.645-3.560
Acute GVHD .014 .026 1.658 1.063-2.586
Extensive cGVHD
Univariate
P-Value
Multivariate
P-Value HR 95% CI
Disease .054 .160 0.846 0.670-1.068
No HLA mismatch .069 .727 0.801 0.232-2.773
No Rtx .053 .035 2.673 1.070-6.675
No ATG <.001 <.001 4.354 2.261-8.384
No Remission .070 .978 0.990 0.487-2.013
No aGVHD .046 .102 1.515 0.921-2.493
Limited cGVHD
Univariate
P-Value
Multivariate
P-Value HR 95% CI
Male sex .075 .177 2.423 0.671-8.746
Disease .011 .026 1.469 1.047-2.060
No Rtx .088 .040 0.328 0.113-0.950
PFS
Univariate
P-value
Multivariate
P-Value HR 95% CI
No HLA mismatch .006 .038 0.507 0.267-0.963
No Rtx .306 .252 1.652 0.700-3.901
No RT .001 .009 0.434 0.232-0.814
Nonrelapse
Mortality
Univariate
P-Value
Multivariate
P-Value HR 95% CI
Male sex .097 .094 2.312 0.866-6.174
Age <55 years .042 .038 0.378 0.150-0.950
No Rtx .055 .074 0.449 0.187-1.081
ATG indicates antithymocyte globulin; CI, confidence interval; GVHD,
graft-versus-host disease; aGVHD, acute graft-versus-host disease;
cGVHD, chronic graft-versus-host disease; HLA, human leukocyte anti-
gen; HR, hazard ratio; PFS, progression-free survival; RT, radiotherapy;
Rtx, rituximab within 6 months prior to RICT.
P-values <.05 are considered significant.Impact of Rtx Treatment Prior to RICTon
aGVHD and cGVHD
The incidence of aGVHD was analyzed by both
univariate and multivariate analysis. There was no sig-
nificant difference in the incidence of grade II-IV and
grade III-IV between the Rtx (48.2% grade II-IV, n5
14; 17.9% grade III-IV, n 5 5) and the no-Rtx group
(45.7% grade II-IV, n 5 64; and 15.6% grade III-IV,
n5 22) (Figure 2A and B). However, the median onset
of grade III-IV aGVHDwas significantly earlier in the
Rtx compared to the no-Rtx group (Rtx group 0.60
months, no-Rtx group 1.60 months; P 5 .013)
(Figure 2C). Only ATG prevented grade III-IV
aGVHD significantly (P 5 .041; hazard ratio [HR]
2.57; 95% confidence interval [CI]: 1.04-6.38) in mul-
tivariate analysis with Cox regression (Table 2).
To assess whether Rtx treatment prior to RICT
prevents the development of limited and extensive
cGVHD, first the overall frequency of limited and ex-
tensive cGVHD was determined and was not signifi-
cantly different between the Rtx and the no-Rtx
group (42.5% [n 5 10] versus 54.9% [n 5 69], P 5
.468), in neither uni- nor multivariate analysis
(Figure 3A and Table 2). However, in the Rtx group
20.1% of patients developed extensive cGVHD (n 5
5), whereas in the no-Rtx group, 45.8% of patients de-
veloped extensive cGVHD (n 5 58) (P 5 .053)
(Figure 3B).Themain sites affectedwere skin, liver,mu-
cosae, and lung, with no profound difference between
the Rtx and the no-Rtx group (Table 1). After multivar-
iate analysis significantly less extensive cGVHDwas de-
tected in patients treated with Rtx (P 5 .035, HR 2.67
[95% CI: 1.07-6.68]) (Table 2). Only the application
of ATG as part of the conditioning regimen (P\ .001,
HR 4.35 [95% CI: 2.26-8.38]), but no other analyzed
factors, also decreased the incidence of extensive
cGVHD in a multivariate analysis. Vice versa, limited
cGVHD was increased in the Rtx group (25.6% [n 5
5]) compared to the no-Rtx group (12.9% [n 5 11],
P5 .088) (Figure3C).Again, thisdifference reached sig-
nificance after multivariate analysis (P5 .040, HR 0.33
[95% CI: 0.11-0.95]) (Table 2). In summary, Rtx treat-
mentprior toRICTdidnot affect the frequencyofgradeII-IV or III-IV aGVHD, but substantially attenuated
extensive cGVHD and thereby presumably increased
the frequency of limited cGVHD.
Figure 3. 1-Kaplan-Meier curves of total cGVHD (A) extensive cGVHD (B), and limited cGVHD (C) in patients who received Rtx prior to RICTand in
patients who did not.
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a Difference in Either PFS or OS
Frequently, manipulations that result in a reduc-
tion of GVHD are also associated with a reduction
of GVL and vice versa [1,2]. Therefore, it was assessed
whether host B cell depletion by Rtx treatment might
not only impair GVHD, but also influence GVL. As
surrogate marker for GVL, PFS was assessed sepa-
rately in the Rtx and no-Rtx group. PFS was decreased
by HLA mismatch (P 5 .038, HR 0.51 [95%
CI: 0.27-0.96]) and radiotherapy as part of the treat-
ment regimen prior to RICT (P 5 .009, HR 0.43
[95% CI: 0.23-0.81]). Although Rtx treatment was
associated with a significantly reduced incidence of
cGVHD, PFS was not influenced (P 5 .306)
(Figure 4A and Table 2) by any other analyzed factors
including type of disease. Also, OS at 40 months did
not differ significantly (P 5 .159) between the Rtx
group (n 5 18; 61.4%) and no-Rtx group (n 5 103;
67.4%) (Figure 4B). This observation is surprising,
as PFS and OS [16], in contrast to aGVHD and
cGVHD [7,17], might have been heavily influenced
by the imbalance in the type of disease in this study co-
hort. However, the low number for certain entities in
this study cohort might have hampered the analysis. Insummary, our data demonstrate a reduced cGVHD in
Rtx treated patients, whereas GVL is not affected.DISCUSSION
B cells play an important, but yet unclear role in the
pathogenesis of cGVHD [2,4], and B cell depletion of
donor B cells after allo-SCTwith themonoclonal anti-
CD20 antibody, Rtx, has been shown to improve ste-
roid refractory cGVHD [5-8]. We asked whether B
cell depletion by Rtx prior to RICT could decrease
the incidence of cGVHD, and preemptive B cell deple-
tion could therefore be a strategy to prevent this major
complication after allo-SCT. Our data indeed indicate
that Rtx treatment prior to RICT decreases the inci-
dence of extensive cGVHD, whereas relapse rate was
not influenced. This result is in contrast to a previous
study that retrospectively compared aGVHD and
cGVHD in 35 leukemia patients who received Rtx,
and 31 control patients [9]. The authors reported no
influence of rituximab on the incidence of cGVHD,
and a possible, but not significant, decrease of the inci-
dence of aGVHD. The main explanation for this dif-
ference might be the myeloablative conditioning
Figure 4. Kaplan-Meier curves of PFS (A) and OS (B) in patients who received Rtx prior to RICT and in patients who did not.
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thus also B cells. Consequently, the reported overall in-
cidence of cGVHD in both arms was very low (11%).
A significantly shorter follow-up period in Rtx pa-
tients than in patients who did not receive Rtx might
have influenced the incidence of cGVHD. However,
the latest time point of onset of extensive cGVHD
was 18.2 months (median 5.0 months [range: 1.5-
18.2 months]), and the median follow-up was in both
groups .20 months. So, even though the follow-up
of the Rtx group was shorter than the follow-up of
the no-Rtx group, it was still long enough for extensive
cGVHD to develop.
B cells have been suggested to be the final effector
cells in cGVHD by secreting interleukin (IL) 6,
a known fibroblast growth factor [18]. However, in pa-
tients of whom B cell counts were available at longer
follow-up (6 or 9 months post-RICT), no significant
differences could be observed in total B cell counts at
the onset of cGVHD, and in most patients a full donor
chimerism was reached (data not shown). This sug-
gests that the early depletion of most likely host B cells
rather than donor B cells are important for the devel-
opment of cGVHD. Thus, alternative mechanisms
must be responsible for the reduced incidence of ex-
tensive cGVHD if patients are treated with Rtx prior
to RICT. Host B cells have been proposed to serve
as professional antigen-presenting-cells (APCs), pres-
ent minor histocompatibility antigens, and induce
GVL and GVHD [19]. In this light, our data suggest
that host antigen-presenting B cells are under certain
conditions [20] required for initiating priming of
donor T cells, which mediate maximum GVHD but
not substantially GVL. Thus, host B cells might rather
influence shaping of a self-reactive donor T cell reper-
toire than directly mediating cGVHD.
Wecanonly speculate as towhyRtx-treatedpatients
who developed grade III-IV aGVHD developed it ear-
lier, and conclusions have to be drawn very cautiously
because of the very low number of patients in the Rtx
arm (n5 5). One explanation for thismore rapid courseof aGVHD could be that B cells serve as regulatory B
cells, as reported inmice, and provide IL-10 to attenuate
the course of the disease [21]. However, we cannot ex-
clude that also other modulators of the immune system
such as regulatoryTcells [22,23] orTh17 [24] cellswere
indirectly affected by B cell depletion.
We are aware of major limitations of this study,
such as an imbalance in disease, which primarily might
have influenced the analysis of PFS andOS, but not the
incidence of aGVHD and cGVHD. Thus, our data
suggest that most likely host B cells are important in
the pathogenesis of cGVHD. Preemptive B cell deple-
tion might therefore be a valuable strategy to substan-
tially reduce extensive cGVHD after RICT.ACKNOWLEDGMENTS
Financial disclosure: This work was supported by
a grant from the Dutch Cancer Society, KWF 2006-
3685.The authors have no conflicting financial interests.REFERENCES
1. Appelbaum FR. Haematopoietic cell transplantation as immu-
notherapy. Nature. 2001;411:385-389.
2. Lee SJ. New approaches for preventing and treating chronic
graft-versus-host disease. Blood. 2005;105:4200-4206.
3. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E.
Autoimmunity after allogeneic bone marrow transplantation.
A study of 53 long-term-surviving patients. Transplantation.
1988;46:238-240.
4. Sun Y, Tawara I, Toubai T, Reddy P. Pathophysiology of acute
graft-versus-host disease: recent advances. Transl Res. 2007;150:
197-214.
5. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of
chronic graft-versus-host disease with anti-CD20 chimeric
monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:
505-511.
6. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al.
Anti-CD20 monoclonal antibody treatment in 6 patients with
therapy-refractory chronic graft-versus-host disease. Blood.
2004;104:2603-2606.
678 Biol Blood Marrow Transplant 15:671-678, 2009S. van Dorp et al.7. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-re-
fractory chronic graft-versus-host disease. Blood. 2006;108:
756-762.
8. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory
chronic GVHD with rituximab: a GITMO study. Bone Marrow
Transplant. 2007;40:273-277.
9. Kebriaei P, Saliba RM, Ma C, et al. Allogeneic hematopoietic
stem cell transplantation after rituximab-containing myeloabla-
tive preparative regimen for acute lymphoblastic leukemia. Bone
Marrow Transplant. 2006;38:203-209.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of marrow from
HL-A-matched sibling donors. Transplantation. 1974;18:
295-304.
11. Filipovich AH,Weisdorf D, Pavletic S, et al. National Institutes
of Health consensus development project on criteria for clinical
trials in chronic graft-versus-host disease: I. Diagnosis and stag-
ing working group report. Biol Blood Marrow Transplant. 2005;
11:945-956.
12. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host
disease. Biol Blood Marrow Transplant. 2003;9:215-233.
13. Berinstein NL,Grillo-Lopez AJ,White CA, et al. Association of
serum Rituximab (IDEC-C2B8) concentration and anti-tumor
response in the treatment of recurrent low-grade or follicular
non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995-1001.
14. Cartron G, Blasco H, Paintaud G, Watier H, Le GC. Pharma-
cokinetics of rituximab and its clinical use: thought for the best
use? Crit Rev Oncol Hematol. 2007;62:43-52.
15. Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution
after rituximab treatment of lymphoma recapitulates B cell
ontogeny. Clin Immunol. 2007;122:139-145.16. Antin JH. Reduced-intensity stem cell transplantation: ‘‘.
whereof a little More than a little is by much too much.’’ King
Henry IV, part 1, I, 2.Hematology Am Soc Hematol Educ Program.
2007;2007:47-54.
17. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-ver-
sus-host disease after allogeneic peripheral-blood stem-cell and
bone marrow transplantation: a meta-analysis. J Clin Oncol.
2001;19:3685-3691.
18. Wynn TA. Common and unique mechanisms regulate fibrosis
in various fibroproliferative diseases. J Clin Invest. 2007;117:
524-529.
19. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for
B cells in T cell priming to minor histocompatibility antigens
and development of graft-versus-host disease. Bone Marrow
Transplant. 1995;16:289-295.
20. Matte CC, Liu J, Cormier J, et al. Donor APCs are required
for maximal GVHD but not for GVL. Nat Med. 2004;10:
987-992.
21. Rowe V, Banovic T, MacDonald KP, et al. Host B cells pro-
duce IL-10 following TBI and attenuate acute GVHD after al-
logeneic bone marrow transplantation. Blood. 2006;108:
2485-2492.
22. Nguyen VH, Shashidhar S, Chang DS, et al. The impact of reg-
ulatory T cells on T-cell immunity following hematopoietic cell
transplantation. Blood. 2008;111:945-953.
23. Zhao D, Zhang C, Yi T, et al. In vivo activated CD1031CD41
regulatory T cells ameliorate ongoing chronic GVHD. Blood.
2008;112:2129-2138.
24. Yi T, Zhao D, Lin CL, et al. Absence of donor Th17 leads to
augmented Th1 differentiation and exacerbated acute graft ver-
sus host disease. Blood. 2008;112:2101-2110.
